Literature DB >> 21267813

[Paraneoplastic syndromes in lung cancer].

H-P Hauber1.   

Abstract

Paraneoplastic syndromes occur in approximately 10% of all patients with lung cancer. They can be the first manifestation of the disease or of a recurrence. Endocrine, haematological, neuromuscular, dermatological, renal, and metabolic syndromes as well as syndromes involving the connective tissue and constitutional syndromes can be distinguished based on their clinical symptoms. In this review, the epidemiology, pathogenesis, clinical signs and treatment options for the clinically important paraneoplastic syndromes in lung cancer are discussed. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 21267813     DOI: 10.1055/s-0030-1256118

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  5 in total

1.  [Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies].

Authors:  M Frackowiak; M Kowar; Ch Sippel; K Wilhelm; Y-D Ko; A H Jacobs
Journal:  Nervenarzt       Date:  2020-02       Impact factor: 1.214

Review 2.  Paraneoplastic syndromes in small cell lung cancer.

Authors:  Zaid Soomro; Michael Youssef; Shlomit Yust-Katz; Ali Jalali; Akash J Patel; Jacob Mandel
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

3.  BetaHCG secretion by a pulmonary adenocarcinoma.

Authors:  Cécile Vicier; Emeline Tabouret; Agnès Tallet; Anthony Gonçalves; Bruno Chetaille; Patrice Viens; Anne Madroszyk
Journal:  World J Surg Oncol       Date:  2013-09-14       Impact factor: 2.754

Review 4.  Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.

Authors:  In-Sun Hong
Journal:  Exp Mol Med       Date:  2016-07-01       Impact factor: 8.718

5.  Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.

Authors:  Montserrat Miret; Erzsébet Horváth-Puhó; Anouk Déruaz-Luyet; Henrik Toft Sørensen; Vera Ehrenstein
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.